Novo (NYSE: NVO) has tapped the Swedish drug-delivery developer Nanexa to develop long-acting injectable platforms for its peptide meds, with a global licensing deal worth €1.165 billion, or about $1.32 billion U.S. The deal will support up to five R&D programs targeting monthly and quarterly injections, as the drugmaker looks to extend the reach of […]
GLP-1s
Fractyl says its single catheter treatment maintained most GLP-1 weight loss
Fractyl Health (NASDAQ: GUTS) reported randomized clinical trial results demonstrating that patients maintained up to 84% of GLP-1-induced weight loss with its Revita technology one year after discontinuing GLP-1 medication, the company announced today. “The success of GLP-1 medicines has created a new unsolved problem: what happens when patients stop. Most do stop eventually, whether […]
ResMed revenue up 10% in Q2 — but GLP-1 questions remain
ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 results. The results, out after market close yesterday evening, came more than a month after the FDA approved Eli Lilly’s GLP-1 drug Zepbound (tirzepatide) as the first and only prescription drug to treat sleep apnea. CMS […]
Analysts remain high on ResMed despite potential sleep apnea benefits from GLP-1s
William Blair analysts say that new data supporting the use of GLP-1s in patients with sleep apnea shouldn’t displace companies like ResMed in the market. GLP-1 receptor agonists, like Ozempic and Wegovy, provide therapy for diabetes and can lead to weight loss. Beyond impacting the diabetes industry, questions have arisen over their overall impact on […]
Real-world data backs Abbott FreeStyle Libre CGM in tandem with GLP-1s
Abbott today announced data from two real-world studies highlighting the success of its CGM when used with GLP-1 drugs. Data showed that people with type 2 diabetes using GLP-1s with FreeStyle Libre had a greater improvement in HbA1c compared to GLP-1s alone. Abbott presented the findings at the Advanced Technologies & Treatments for Diabetes (ATTD) […]
Medtronic’s mid-single digit revenue growth continues
Medtronic today reported second-quarter results that beat the Wall Street analysts’ consensus, with the world’s largest medtech company reporting strength across businesses and geographies. Along with a raised full-year guidance, the news sent MDT shares up more than 4% to $78.74 apiece by afternoon trading today. MassDevice‘s MedTech 100 Index was up slightly. The positive […]
Stryker beats The Street in Q3, CEO Lobo allays GLP-1 fears
Stryker shares fell slightly this morning on third-quarter results that topped the consensus forecast. Shares of SYK dipped 1.8% at $273.22 apiece in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 1.4%. The Kalamazoo, Michigan-based company posted profits of $692 million, equaling $1.80 […]
Intuitive leaders weigh in on GLP-1 drugs and surgical robotics procedures
Intuitive Surgical executives say they see benefits to their business from GLP-1 weight loss drugs, even if investors aren’t quite so sure. Intuitive’s stock slid in after-hours trading today after the company posted Q3 results that exceeded analysts’ expectations on profits but fell short on sales. Even if they had beat The Street on both […]
Analysts: GLP-1 drugs should have minor impact on insulin pump market — but will boost CGMs
Based on conversations with diabetes experts, analysts are playing down the potentially negative impact of GLP-1 receptor agonists on the diabetes technology industry. The GLP-1 drug class, which includes Ozempic and Wegovy, has cast a shadow of doubt over diabetes technology of late. This therapeutic class, a glucagon-like peptide 1, has proven to lead to […]
